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A new clinical diagnostic matrix for epidermolysis bullosa 
Linked article Vamsi et al. Br J Dermatol 2017; 
Globally, there are close to 500,000 people living with various forms of the inherited 
blistering skin condition, epidermolysis bullosa (EB), although most of the comprehensive 
epidemiological data on EB has been extrapolated from just a few countries.1 Clinically and 
genetically, EB is a heterogeneous group of disorders, with at least 33 recognisable 
phenotypic variants (9 major) and 18 candidate genes listed in a 2014 international 
consensus report,2 although new EB genes continue to be added, even in 2016.3,4 Being able 
to diagnose EB accurately is an important part of clinical management given the range of 
disease complications, management concerns, and prognoses associated with the diverse 
spectrum of EB subtypes.2 Making rapid and accurate diagnoses of EB may be relatively 
straightforward in some countries supported by expert clinical teams and specialised 
laboratories that can assess skin biopsies (immunohistochemistry, transmission electron 
microscopy) and perform gene sequencing analyses – but such diagnostic infrastructure is 
often simply not available in many countries, where all that is possible is clinical 
examination by dermatologists, most of whom are unfamiliar with the nuances of clinical 
and laboratory diagnostic criteria for EB. To address this shortfall, Vamsi et al.5 set out to 
assess whether a set of distinctive clinical features could be formulated that would help 
non-experts make more accurate diagnoses of EB. The premise was that, although a single 
clinical feature might not be pathognomonic for any one particular form of EB, grouping 
several features together might increase the diagnostic accuracy in distinguishing between 
the different subtypes of EB. Thus emerged a “clinical diagnostic matrix” that lists 19 
different recordable metrics (derived from history and examination), with the vision that 
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certain sets of these grouped metrics could help steer the clinician to just one of the 9 major 
clinical diagnostic subtypes of EB, thereby generating a single most likely diagnosis. The 
authors tested the matrix in 74 genetically characterised cases of EB and found high 
concordance rates (matrix/molecular diagnostics) as well as very good diagnostic agreement 
between clinicians using the matrix. Inevitably, of course, such a reductionist approach is 
bound to have some inherent weaknesses, and it was clear that trying to apply the matrix to 
individuals less than 6 months of age led to loss of diagnostic discrimination and value. 
Nevertheless, in older subjects, this first study does appear to have diagnostic merit. The 
next step will be for other dermatologists around the world to try out the matrix on their 
patients, old and new, to see whether their own observations validate the initial findings. 
Thereafter, generating an online version of the clinical diagnostic matrix is likely to provide 
both a useful resource for future refinements to the sets of diagnostic metrics, as well as the 
generation of considerable data of global epidemiological importance. 
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